Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients

BACKGROUND: Bezlotoxumab significantly reduces the incidence of recurrent Clostridioides difficile infection (CDI); however, limited data are available in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients. METHODS: We conducted a single-center retrospective analysis com...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Open Forum Infect Dis
Egile Nagusiak: Johnson, Tanner M, Howard, Amanda H, Miller, Matthew A, Allen, Lorna L, Huang, Misha, Molina, Kyle C, Bajrovic, Valida
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2021
Gaiak:
Major Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274359/
https://ncbi.nlm.nih.gov/pubmed/34262988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofab294
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak